-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised mecasermin for patients
with severe growth failure with primary insulin-like growth factor-1
deficiency (IGFD).

Severe growth failure with IGFD and listing dates

Severe growth failure with IGFD is a genetic disease in patients causing
short stature and slow growth.

Listing dates are:

-   mecasermin 1 October 2022

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

Processing written authority approval requests

Processing Complex Authority Required Listings

Work Optimiser for staff

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
